| Dr Jeremiah Brent Seely, MD | |
|
1323 E. Franklin St., Suite 105, Hillsboro, TX 76645 | |
| (254) 582-7481 | |
| (254) 580-1584 |
| Full Name | Dr Jeremiah Brent Seely |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 18 Years |
| Location | 1323 E. Franklin St., Hillsboro, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073753448 | NPI | - | NPPES |
| 200865802 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | M8984 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Hospice | Waco, TX | Hospice |
| Hill Regional Hospital | Hillsboro, TX | Hospital |
| Providence Health Center | Waco, TX | Hospital |
| West Rest Haven Inc | West, TX | Nursing home |
| Town Hall Estates Whitney Inc | Whitney, TX | Nursing home |
| Homestead Nursing And Rehabilitation Of Itasca | Itasca, TX | Nursing home |
| Homestead Nursing And Rehabilitation Of Hillsboro | Hillsboro, TX | Nursing home |
| Town Hall Estates | Hillsboro, TX | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Heart Of Texas Community Health Center, Inc. | 1153370242 | 95 |
| Providence Health Alliance | 6305731068 | 129 |
News Archive
Royal Philips today announced the range of its Magnetic Resonance (MR) solutions to be showcased at the International Society for Magnetic Resonance in Medicine's (ISMRM) 23rd Annual Meeting & Exhibition in Toronto, Canada.
Today, the U.S. Food and Drug Administration authorized marketing of a new device intended to be worn around the neck of athletes aged 13 years and older during sports activities to aid in the protection of the brain from the effects associated with repetitive sub-concussive head impacts.
The U.S. Court of Appeals for the District of Columbia on Tuesday vacated an earlier decision that would have provided terminally ill patients with expanded access to experimental medications and likely will rehear the case next summer, Dow Jones/Wall Street Journal reports (Wilde Mathews, Dow Jones/Wall Street Journal, 11/21).
Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.
According to an article in the January 2010 edition of Drugs In Dermatology (abstract available at http://jddonline.com ), the use of botulinum type A toxins such as Botox and Dysport may offer a cost efficient alternative to the use of selective serotonin reuptake inhibitors.
› Verified 9 days ago
| Entity Name | Providence Health Alliance |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932210838 PECOS PAC ID: 6305731068 Enrollment ID: O20040220000307 |
News Archive
Royal Philips today announced the range of its Magnetic Resonance (MR) solutions to be showcased at the International Society for Magnetic Resonance in Medicine's (ISMRM) 23rd Annual Meeting & Exhibition in Toronto, Canada.
Today, the U.S. Food and Drug Administration authorized marketing of a new device intended to be worn around the neck of athletes aged 13 years and older during sports activities to aid in the protection of the brain from the effects associated with repetitive sub-concussive head impacts.
The U.S. Court of Appeals for the District of Columbia on Tuesday vacated an earlier decision that would have provided terminally ill patients with expanded access to experimental medications and likely will rehear the case next summer, Dow Jones/Wall Street Journal reports (Wilde Mathews, Dow Jones/Wall Street Journal, 11/21).
Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.
According to an article in the January 2010 edition of Drugs In Dermatology (abstract available at http://jddonline.com ), the use of botulinum type A toxins such as Botox and Dysport may offer a cost efficient alternative to the use of selective serotonin reuptake inhibitors.
› Verified 9 days ago
| Entity Name | Heart Of Texas Community Health Center, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568191492 PECOS PAC ID: 1153370242 Enrollment ID: O20050114000813 |
News Archive
Royal Philips today announced the range of its Magnetic Resonance (MR) solutions to be showcased at the International Society for Magnetic Resonance in Medicine's (ISMRM) 23rd Annual Meeting & Exhibition in Toronto, Canada.
Today, the U.S. Food and Drug Administration authorized marketing of a new device intended to be worn around the neck of athletes aged 13 years and older during sports activities to aid in the protection of the brain from the effects associated with repetitive sub-concussive head impacts.
The U.S. Court of Appeals for the District of Columbia on Tuesday vacated an earlier decision that would have provided terminally ill patients with expanded access to experimental medications and likely will rehear the case next summer, Dow Jones/Wall Street Journal reports (Wilde Mathews, Dow Jones/Wall Street Journal, 11/21).
Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.
According to an article in the January 2010 edition of Drugs In Dermatology (abstract available at http://jddonline.com ), the use of botulinum type A toxins such as Botox and Dysport may offer a cost efficient alternative to the use of selective serotonin reuptake inhibitors.
› Verified 9 days ago
| Entity Name | Hospital Care Consultants Of Hillsboro Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114449766 PECOS PAC ID: 9537431499 Enrollment ID: O20170828002027 |
News Archive
Royal Philips today announced the range of its Magnetic Resonance (MR) solutions to be showcased at the International Society for Magnetic Resonance in Medicine's (ISMRM) 23rd Annual Meeting & Exhibition in Toronto, Canada.
Today, the U.S. Food and Drug Administration authorized marketing of a new device intended to be worn around the neck of athletes aged 13 years and older during sports activities to aid in the protection of the brain from the effects associated with repetitive sub-concussive head impacts.
The U.S. Court of Appeals for the District of Columbia on Tuesday vacated an earlier decision that would have provided terminally ill patients with expanded access to experimental medications and likely will rehear the case next summer, Dow Jones/Wall Street Journal reports (Wilde Mathews, Dow Jones/Wall Street Journal, 11/21).
Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.
According to an article in the January 2010 edition of Drugs In Dermatology (abstract available at http://jddonline.com ), the use of botulinum type A toxins such as Botox and Dysport may offer a cost efficient alternative to the use of selective serotonin reuptake inhibitors.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeremiah Brent Seely, MD Po Box 18962, Belfast, ME 04915-4084 Ph: (800) 566-5050 | Dr Jeremiah Brent Seely, MD 1323 E. Franklin St., Suite 105, Hillsboro, TX 76645 Ph: (254) 582-7481 |
News Archive
Royal Philips today announced the range of its Magnetic Resonance (MR) solutions to be showcased at the International Society for Magnetic Resonance in Medicine's (ISMRM) 23rd Annual Meeting & Exhibition in Toronto, Canada.
Today, the U.S. Food and Drug Administration authorized marketing of a new device intended to be worn around the neck of athletes aged 13 years and older during sports activities to aid in the protection of the brain from the effects associated with repetitive sub-concussive head impacts.
The U.S. Court of Appeals for the District of Columbia on Tuesday vacated an earlier decision that would have provided terminally ill patients with expanded access to experimental medications and likely will rehear the case next summer, Dow Jones/Wall Street Journal reports (Wilde Mathews, Dow Jones/Wall Street Journal, 11/21).
Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.
According to an article in the January 2010 edition of Drugs In Dermatology (abstract available at http://jddonline.com ), the use of botulinum type A toxins such as Botox and Dysport may offer a cost efficient alternative to the use of selective serotonin reuptake inhibitors.
› Verified 9 days ago
Dr. Wesley C Marshall, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1323 E Franklin St, Suite 105, Hillsboro, TX 76645 Phone: 254-582-7481 Fax: 254-580-1584 | |
Jason R Bauerschlag, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1323 E Franklin St, Suite 105, Hillsboro, TX 76645 Phone: 254-582-7481 Fax: 254-580-1584 | |
Britney Lee Burnett, FNP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 Corsicana Hwy, Hillsboro, Tx 76645, Hillsboro, TX 76645 Phone: 254-651-1769 | |
Dr. Steve Nelson Martin Jr., MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 101 Circle Dr, Hillsboro, TX 76645 Phone: 254-580-8911 | |
James M Earhart, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1323 E Franklin St, Suite 105, Hillsboro, TX 76645 Phone: 254-582-7481 Fax: 254-580-1584 | |
Christopher W Teague, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1323 E. Franklin St., Suite 105, Hillsboro, TX 76645 Phone: 254-582-7481 Fax: 254-580-1584 |